Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ917MR)

This product GTTS-WQ917MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ917MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2688MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ7708MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ4950MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ3768MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ13111MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ9482MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ9979MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KD-247
GTTS-WQ10117MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LAG-525
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW